<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821247</url>
  </required_header>
  <id_info>
    <org_study_id>18033</org_study_id>
    <secondary_id>SIRIUS/OS-CY-1668</secondary_id>
    <nct_id>NCT02821247</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece</brief_title>
  <acronym>PERSEUS-GR</acronym>
  <official_title>A Prospective obsERvational Study to asSEss the Effectiveness of Intravitreal Aflibercept Injection in roUtine Clinical Practice in Treatment Naive patientS With Wet Age-related Macular Degeneration in Greece</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, multi-center, study. The study will be conducted in&#xD;
      approximately 12 ophthalmological clinics and practices throughout Greece. It is planned to&#xD;
      collect data on treatment of wet Age related Macular Degeneration (wAMD) from about 120&#xD;
      patients for which the decision to treat with intravitreal aflibercept injections is made at&#xD;
      the discretion of the attending physician, according to his/her medical practice. Visits will&#xD;
      be performed at baseline, aflibercept first injection (if different from enrollment) and at&#xD;
      12 and 24 months. The 12 and 24 month comprise the data collection visits during which any&#xD;
      data generated in the period preceding these visits will be recorded.&#xD;
&#xD;
      All required information for the purposes of this study will be collected using electronic&#xD;
      Case Record Form (eCRF). The web-based electronic data capture (EDC) application will be&#xD;
      specifically designed for the needs of the study and will adhere to all applicable data&#xD;
      protection regulations and requirements with regard to electronic records.&#xD;
&#xD;
      The study observation period for each patient enrolled in this study is the time from the&#xD;
      beginning of treatment with intravitreal aflibercept injection up to two years or until&#xD;
      discontinuation of intravitreal aflibercept injection-treatment due to any reason including&#xD;
      withdrawal of consent or patient loss from follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and background Age-related macular degeneration (AMD) is the most common&#xD;
      degenerative disease of the macula and the most common cause of legal blindness in the&#xD;
      Western world. AMD is a disease of the elderly affecting 10% of individuals aged 65 to 74&#xD;
      years and 30% of those aged 75 to 85 years. Two forms of AMD can be distinguished. The dry&#xD;
      form is more benign accounting for 90% of all AMD cases, but only for 10% of cases of&#xD;
      blindness due to AMD. On the other hand wet AMD affects only 10% of AMD patients. However, it&#xD;
      is more aggressive and rapidly progresses. Wet AMD (wAMD) accounts for 80% of cases of severe&#xD;
      visual impairment and represents the majority of cases of legal blindness. Thus, wet or&#xD;
      neovascular AMD is a disease with a great impact on both visual acuity and patients' quality&#xD;
      of life.&#xD;
&#xD;
      About 1% of the population is affected by wAMD between 65-74 years of age, 5% between 75-84&#xD;
      years of age and 13% in people 85+ years. Given that wAMD is a strongly age-dependent disease&#xD;
      its prevalence is expected to significantly increase in western countries (including Greece)&#xD;
      in the near future. Therefore, early diagnosis and proper treatment will be a major public&#xD;
      health concern.&#xD;
&#xD;
      AMD is diagnosed by stereoscopic biomicroscopy and additional examinations of the macula,&#xD;
      such as fluorescein angiography (FA), indocyanine green angiography (ICGA) and optical&#xD;
      coherence tomography (OCT). The patient's visual status can be monitored with the Snellen&#xD;
      chart and Early Treatment Diabetic Retinopathy Study (ETDRS) chart, the Snellen chart being&#xD;
      most often used in Greece.&#xD;
&#xD;
      Wet AMD is caused by choroidal neovascularization (CNV) whereby new abnormal blood vessels&#xD;
      spread beneath the retina. These vessels may rupture and cause retinal damage. In addition,&#xD;
      vascular leakage may cause thickening and oedema of the retina, which is thought to&#xD;
      contribute to vision loss. Vascular endothelial growth factor (VEGF) and placental growth&#xD;
      factor (PlGF) play a pivotal role in this scenario. VEGF-A and PlGF are members of the VEGF&#xD;
      family of angiogenic factors that act as potent mitogenic, chemotactic, and vascular&#xD;
      permeability factors for endothelial cells. VEGF acts via two receptor tyrosine&#xD;
      kinases-VEGFR-1 and VEGFR-2-which are located on the surface of endothelial cells. PlGF binds&#xD;
      only to VEGFR-1, which is also present on the surface of leukocytes. Excessive activation of&#xD;
      these receptors by VEGF-A can induce pathological neovascularization and excessive vascular&#xD;
      permeability. PlGF can synergize with VEGF-A in these processes, and is also known to promote&#xD;
      leukocyte infiltration and vascular inflammation.&#xD;
&#xD;
      Treatment paradigms for wet AMD have changed tremendously since anti-VEGF treatment&#xD;
      (inhibition of all VEGF-A Isoforms) was introduced. As a consequence, most previous therapy&#xD;
      approaches lost significance and are applied in rare cases only. The pan-anti-angiogenesis&#xD;
      treatment with ranibizumab was the first to show significant improvements in visual acuity of&#xD;
      patients suffering from wAMD, thus becoming the first-choice therapy for most patients. The&#xD;
      phase III clinical trials MARINA and ANCHOR have shown that ranibizumab applied every month&#xD;
      is highly effective in improving visual impairment. However, in addition to the small risk of&#xD;
      endophthalmitis associated with intravitreal injections, monthly treatment, which may&#xD;
      continue for a patient's lifetime, is extremely burdensome to patients, their caregivers,&#xD;
      ophthalmologists and the healthcare system. As a consequence, in clinical practice the&#xD;
      monthly treatment regimen of ranibizumab is often altered to less frequent dosing intervals&#xD;
      to reduce the associated treatment burden, although this may result in notably reduced&#xD;
      efficacy.&#xD;
&#xD;
      Results from observational studies such as WAVE and AURA, which investigated wAMD patients&#xD;
      treated with Lucentis (ranibizumab) in a real life setting in western countries, suggest that&#xD;
      these patients are not treated according to a continuous treatment pattern and are also&#xD;
      undertreated resulting in suboptimal treatment effects. In the WAVE Study (n=2587) patients&#xD;
      received 4.3 injections during the first treatment year and the visual acuity returned to the&#xD;
      baseline visual acuity at the end of the year. In the AURA study (n=420), German cohort,&#xD;
      patients received 4.3 injections in the first year and only 2.1 injections during the second&#xD;
      year. The visual acuity declined during year 1 to -1.4 letters and further declined to -2.4&#xD;
      letters during year 2 compared to baseline. In the AURA study (n =365), Italian cohort,&#xD;
      patients received 3.9 injections in the first year and only 1.4 injections during the second&#xD;
      year. The visual acuity declined during year 1 to 0 letters and further declined to -2.9&#xD;
      letters during year 2 compared to baseline .&#xD;
&#xD;
      Intravitreal aflibercept is the next generation of anti-angiogenesis treatments which also&#xD;
      introduces a new proactive every-other-month treatment regimen (after 3 monthly injections)&#xD;
      in the first year, followed by individually extended treatment intervals afterwards.&#xD;
      Aflibercept is a fusion protein consisting of portions of human VEGF receptors 1 and 2&#xD;
      extracellular domains fused to the Fc portion of human IgG1. It is purified and formulated as&#xD;
      a solution for intravitreal use. As such, aflibercept acts as a soluble decoy receptor that&#xD;
      binds VEGF-A and PlGF with higher affinity than naturally occurring VEGF receptors. Thus&#xD;
      aflibercept competitively inhibits VEGF-A and PIGF binding to the cognate VEGF receptors and&#xD;
      their activation.&#xD;
&#xD;
      Intravitreal aflibercept was recently approved by the European Medicines Agency (EMA) in&#xD;
      November 2012. The aims of this study are to collect data on the effectiveness of&#xD;
      intravitreal aflibercept and to evaluate follow-up as well as treatment patterns in treatment&#xD;
      naive patients with wAMD in routine clinical practice in Greece treated with intravitreal&#xD;
      aflibercept injection.&#xD;
&#xD;
      Research questions and objectives The main objectives of this observational study are to&#xD;
      evaluate the effectiveness of intravitreal aflibercept injection and to describe routine&#xD;
      clinical practice monitoring and treatment patterns in treatment-na誰ve wAMD patients in&#xD;
      Greece.&#xD;
&#xD;
      Primary objective&#xD;
&#xD;
      The primary objective in this study is:&#xD;
&#xD;
        -  To evaluate the effectiveness of intravitreal aflibercept injection by assessing the&#xD;
           change in best corrected visual acuity (BCVA; defined as visual acuity with manifest&#xD;
           refraction) from baseline at the 12-month timepoint, in treatment naive patients with&#xD;
           wAMD in routine clinical practice in Greece.&#xD;
&#xD;
      Secondary objective(s)&#xD;
&#xD;
      The secondary objectives in this study are:&#xD;
&#xD;
        -  To evaluate the effectiveness of intravitreal aflibercept injection by assessing the&#xD;
           change in BCVA (with manifest refraction) from baseline at the 24-month timepoint&#xD;
&#xD;
        -  To evaluate the effectiveness of intravitreal aflibercept injection by assessing the&#xD;
           change in visual acuity with glasses from baseline to the 24-month timepoint&#xD;
&#xD;
        -  To assess the change in central retinal thickness at 12 and 24 months&#xD;
&#xD;
        -  To assess the proportion of patients with no fluid at 12 and 24 months&#xD;
&#xD;
        -  To assess the disease activity monitoring patterns and the treatment patterns used in&#xD;
           routine clinical practice (e.g. number of evaluation visits, injection visits, combined&#xD;
           visits, OCT tests, visual acuity tests, fundoscopy tests, Fluorescein Angiography (FA)&#xD;
           and Indocyanine Green Angiograpy (ICGA tests).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of visual acuity from baseline to 12 months</measure>
    <time_frame>At baseline and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA) (with manifest refraction) from baseline at the 24-month timepoint</measure>
    <time_frame>At baseline, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity with glasses from baseline to the 24-month timepoint</measure>
    <time_frame>At baseline, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal thickness (OCT measurement) at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with no fluid at, 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of routine clinical evaluation (monitoring) visits at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of optical coherence tomography (OCT) assessments per patient</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visual acuity tests</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fundoscopy examinations</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of injection visits at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of combined visits (monitoring and injection) at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fluorescein angiography (FA) tests / patient at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of indocyanine green angiography (ICGA) tests / patient at 12 and 24 months</measure>
    <time_frame>At 12 months, At 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">119</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <description>Adult wet Age Related Macular degeneration (AMD) treatment na誰ve partcipants were treated with intravitreal aflibercept injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept (Eylea, BAY86-5321)</intervention_name>
    <description>Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>VEGF Trap-Eye</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consisted of patients treated with Aphlibercept as first treatment for&#xD;
        wAMD ( Treatment Na誰ve Patients).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment naive patients with wet AMD for whom the decision to be treated with&#xD;
             intravitreal aflibercept injection in accordance with the Summary of Product&#xD;
             Characteristics was made.&#xD;
&#xD;
          -  Patients having signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications as listed in the local Summary of Product Characteristics.&#xD;
&#xD;
          -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.&#xD;
&#xD;
          -  Any prior or concomitant therapy with any other agent (including among others,&#xD;
             anti-VEGF agents and photodynamic therapy) to treat wet AMD in the study eye.&#xD;
&#xD;
          -  Patients with previous exposure to systemic anti-VEGF treatment.&#xD;
&#xD;
          -  Patients participating in an investigational program with interventions.&#xD;
&#xD;
          -  Previous macular surgery, including laser, for any retinal pathology in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Na誰ve Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

